Table 1.
Phenotypic Description of the Cohort and Its Evolution During the Balneotherapy
| All Cohort (n = 96) | Long AD (n = 48) | Recent AD (n = 48) | Long vs Recent | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| D0 | D18 | Pa | D0 | D18 | Pa | D0 | D18 | Pa | p(D0)b | p(D18)b | |
| Gender (% women) | 53.1 | – | – | 54.2 | – | – | 52.1 | – | – | 1 | – |
| Age (years) | 40 ± 20 | – | – | 50 ± 13 | – | – | 31 ± 20 | – | – | 6.2e–06 | – |
| Disease seniority (years) | 26 ± 18 | – | – | 40 ± 13 | – | – | 11 ± 6.1 | – | – | 3.1e–17 | – |
| Age at disease onset (years) | 15 ± 18 | – | – | 9.3 ± 12 | – | – | 20 ± 21 | – | – | 0.011 | – |
| SCORAD | 65 ± 13 | 43 ± 14 | 5.4e–17 | 67 ± 11 | 43 ± 15 | 5e–14 | 64 ± 14 | 43 ± 14 | 1.8e–12 | 0.29 | 0.85 |
| SCORAD A | 45 ± 23 | 28 ± 18 | 4.4e–15 | 43 ± 22 | 26 ± 14 | 1.5e–08 | 46 ± 24 | 30 ± 21 | 5.5e–08 | 0.43 | 0.51 |
| SCORAD B | 13 ± 2.4 | 8.8 ± 2.9 | 2.6e–16 | 13 ± 2.1 | 9 ± 3.2 | 6.3e–09 | 12 ± 2.5 | 8.7 ± 2.7 | 6.6e–09 | 0.061 | 0.75 |
| SCORAD C | 12 ± 3.9 | 6.7 ± 3.4 | 7.4e–16 | 12 ± 3.9 | 6.8 ± 3.4 | 3e–09 | 12 ± 3.8 | 6.5 ± 3.4 | 3.7e–08 | 0.7 | 0.5 |
| SCORAD reduction | 34 ± 15 | – | – | 36 ± 16 | – | – | 33 ± 15 | – | – | 0.2 | – |
| MSP richness | 240 ± 75 | 240 ± 78 | 0.51 | 260 ± 75 | 260 ± 73 | 0.71 | 220 ± 72 | 220 ± 78 | 0.6 | 0.048 | 0.024 |
Notes: P-values were obtained from Wilcoxon (signed-rank) tests. Significant p-values (p ≤ 0.05) are in bold. aP-values are obtained from Wilcoxon signed-rank tests between D0 and D18, in either the whole cohort, the long AD cohort or the recent AD cohort. bP-values are obtained from Wilcoxon tests and compare patients with long AD to patients with recent AD at D0 (p(D0)) or D18 (p(D18)).